PFM
FATE icon

Privium Fund Management’s Fate Therapeutics FATE Stock Holding History

Privium Fund Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Hold
414,311
– – 0.21% 44
2026
Q1 		$497K Buy
414,311
+45,211
+12% +$55K 0.1% 54
2025
Q4 		$363K Buy
369,100
+35,881
+11% +$43.1K 0.07% 52
2025
Q3 		$420K Buy
333,219
+222,129
+200% +$239K 0.08% 53
2025
Q2 		$127K Buy
111,090
+2,064
+2% +$2.4K 0.03% 54
2025
Q1 		$86.1K Buy
109,026
+22,026
+25% +$27K 0.02% 55
2024
Q4 		$144K Buy
87,000
+37,000
+74% +$93.2K 0.03% 61
2024
Q3 		$175K Buy
+50,000
New +$195K 0.04% 76

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Privium Fund Management's FATE Position: Q2 2026 in Review

Privium Fund Management held its Fate Therapeutics (FATE) position steady in Q2 2026 at 414,311 shares worth $1.12M. The position accounts for 0.21% of the portfolio, ranked #44.

Privium Fund Management first reported a position in FATE in Q3 2024 and has held it in 8 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Privium Fund Management held 414,311 shares of Fate Therapeutics worth $1.12M as of Q2 2026.
  • Privium Fund Management left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up 0.21% of Privium Fund Management's portfolio in Q2 2026, its #44 holding.
  • Privium Fund Management first reported a position in Fate Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.